Shanghai, China

Qing Lin

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2025

where 'Filed Patents' based on already Granted Patents

3 patents (USPTO):

Title: Qing Lin: Innovator in Antibody-Drug Conjugates

Introduction

Qing Lin is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates (ADCs). With a total of 3 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

One of Qing Lin's latest patents is a tissue factor-targeted antibody-drug conjugate. This ADC is designed to bind to tissue factor (TF) antigen with high specificity. It boasts high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity. This innovative approach has the potential to enhance the effectiveness of cancer therapies.

Career Highlights

Qing Lin has worked with notable institutions such as Fudan University and Shanghai Miracogen Inc. His experience in these organizations has allowed him to advance his research and contribute to the development of cutting-edge medical technologies.

Collaborations

Qing Lin has collaborated with several professionals in his field, including Ke Yu and Xuesai Zhang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Qing Lin's work in the development of antibody-drug conjugates represents a significant advancement in cancer treatment. His innovative patents and collaborations highlight his commitment to improving healthcare through biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…